Paradiem’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Paradiem’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,872	Closed	-$1.72M	–	104
2023 Q3	$1.72M	Buy	14,872 +1,320	+10%	+$142K	0.52%	75
2023 Q2	$1.39M	Sell	13,552 -22	-0.2%	-$2.32K	0.4%	82
2023 Q1	$1.48M	Sell	13,574 -2,599	-16%	-$287K	0.46%	79
2022 Q4	$1.84M	Buy	16,173 +2,644	+20%	+$220K	0.68%	65
2022 Q3	$837K	Buy	13,529 +700	+5%	+$48.9K	0.32%	85
2022 Q2	$1.02M	Sell	12,829 -470	-4%	-$44.5K	0.39%	79
2022 Q1	$1.5M	Sell	13,299 -18	-0.1%	-$1.75K	0.49%	79
2021 Q4	$1.24M	Buy	13,317 +1,565	+13%	+$171K	0.41%	81
2021 Q3	$1.38M	Sell	11,752 -622	-5%	-$64.6K	0.41%	83
2021 Q2	$1.32M	Buy	12,374 +1,030	+9%	+$94.8K	0.41%	83
2021 Q1	$1.03M	Buy	11,344 +3,124	+38%	+$264K	0.34%	81
2020 Q4	$590K	Buy	+8,220	New	+$611K	0.25%	86

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Paradiem's HZNP Position: Q4 2023 in Review

Paradiem sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 14,872 shares — an estimated $1.72M sold.

Paradiem first reported a position in HZNP in Q4 2020 and held it in 12 quarters. The position peaked at $1.84M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Paradiem reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Paradiem sold 14,872 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.72M.
Paradiem first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 12 quarters.
Paradiem's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.84M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Paradiem's 13F filing for Q4 2023, filed 5 Feb 2024.